GLP-1 receptor agonists in heart failure: how far to expand use? por Walter Suárez Carmona | Ene 23, 2025
Impact of Peroxisome Proliferator-Activated Receptor Agonists on Myosteatosis in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease por Walter Suárez Carmona | Ene 22, 2025
Hepatic function of glucagon-like peptide-1 and its based diabetes drugs por Walter Suárez Carmona | Ene 22, 2025
Is glycaemic control still central in the hierarchy of priorities in type 2 diabetes management? The way forward is to combine glucose control and the prevention of cardiorenal complications por Walter Suárez Carmona | Ene 22, 2025
Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease? por Walter Suárez Carmona | Ene 22, 2025
